MA28021A1 - Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 - Google Patents
Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4Info
- Publication number
- MA28021A1 MA28021A1 MA28851A MA28851A MA28021A1 MA 28021 A1 MA28021 A1 MA 28021A1 MA 28851 A MA28851 A MA 28851A MA 28851 A MA28851 A MA 28851A MA 28021 A1 MA28021 A1 MA 28021A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- dyspepsia
- receptor agonist
- compounds
- agonist activity
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 239000000018 receptor agonist Substances 0.000 title abstract 3
- 229940044601 receptor agonist Drugs 0.000 title abstract 3
- 150000008641 benzimidazolones Chemical class 0.000 title abstract 2
- 201000006549 dyspepsia Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000029493 gastroesophageal disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Structural Engineering (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES US 3 Septembre 2003 60/500,144 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 La présente invention propose un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables, et des compositions contenant de tels composés ainsi que l'utilisation de ces composés pour la production d'un médicament destiné à la maladie du reflux gastro¬¿sophagien, une maladie gastro-intestinale, un trouble de la motilité gastrique, la dyspepsie non ulcéreuse, la dyspepsie fonctionnelle, le syndrome du côlon irritable (IBS), la constipation, la dyspepsie, l'¿sophagite, une maladie gastro-¿sophagienne, les nausées, une maladie du système nerveux central, la maladie d'Alzheimer, un trouble cognitif, les vomissements, la migraine, une maladie neurologique, la douleur, des troubles cardiovasculaires, l'insuffisance cardiaque, l'arythmie cardiaque, le diabète et le syndrome d'apnée. Ces composés ont une activité agoniste des récepteurs 5-HT4 et, ainsi, sont utiles pour le traitement de la maladie du reflux gastro-¿sophagien, de la dyspepsie non ulcéreuse, de la dyspepsie fonctionnelle, du syndrome du côlon irritable ou d'affections similaires chez des mammifères, notamment chez l'homme.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50014403P | 2003-09-03 | 2003-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28021A1 true MA28021A1 (fr) | 2006-07-03 |
Family
ID=34272920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28851A MA28021A1 (fr) | 2003-09-03 | 2006-03-03 | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US7776885B2 (fr) |
| EP (1) | EP1664036B1 (fr) |
| JP (1) | JP3983269B1 (fr) |
| KR (1) | KR100738784B1 (fr) |
| CN (1) | CN100482659C (fr) |
| AP (1) | AP2184A (fr) |
| AR (1) | AR045552A1 (fr) |
| AT (1) | ATE539077T1 (fr) |
| AU (1) | AU2004268840B9 (fr) |
| BR (1) | BRPI0414105B8 (fr) |
| CA (1) | CA2537127C (fr) |
| CR (1) | CR8267A (fr) |
| CY (1) | CY1112321T1 (fr) |
| DK (1) | DK1664036T3 (fr) |
| EA (1) | EA009457B1 (fr) |
| EC (1) | ECSP066407A (fr) |
| ES (1) | ES2377484T3 (fr) |
| GE (1) | GEP20084527B (fr) |
| GT (1) | GT200400174A (fr) |
| HR (1) | HRP20120077T1 (fr) |
| IL (3) | IL173705A (fr) |
| IS (1) | IS8289A (fr) |
| MA (1) | MA28021A1 (fr) |
| MX (1) | MXPA06002550A (fr) |
| NL (1) | NL1026959C2 (fr) |
| NO (1) | NO20061519L (fr) |
| OA (1) | OA13248A (fr) |
| PA (1) | PA8610601A1 (fr) |
| PE (1) | PE20050874A1 (fr) |
| PL (1) | PL1664036T3 (fr) |
| PT (1) | PT1664036E (fr) |
| RS (1) | RS20060145A (fr) |
| SI (1) | SI1664036T1 (fr) |
| TN (1) | TNSN06073A1 (fr) |
| TW (1) | TW200510332A (fr) |
| UA (1) | UA86204C2 (fr) |
| UY (1) | UY28496A1 (fr) |
| WO (1) | WO2005021539A1 (fr) |
| ZA (1) | ZA200601324B (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| UA86204C2 (uk) * | 2003-09-03 | 2009-04-10 | Пфайзер Инк. | Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність |
| TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7728006B2 (en) | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| CA2569654C (fr) | 2004-06-15 | 2010-12-21 | Pfizer Inc. | Derives de benzimidazolone d'acide carboxylique |
| EP1807423B1 (fr) | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Composes de quinolinone-carboxamide |
| ATE441646T1 (de) | 2004-11-05 | 2009-09-15 | Theravance Inc | 5-ht4-rezeptoragonistenverbindungen |
| ATE469897T1 (de) | 2004-12-22 | 2010-06-15 | Theravance Inc | Indazolcarbonsäureamidverbindungen |
| KR100908547B1 (ko) | 2005-02-22 | 2009-07-20 | 화이자 인코포레이티드 | ５ｈｔ４ 수용체 작용제로서의 옥시인돌 유도체 |
| NZ560828A (en) | 2005-03-02 | 2011-01-28 | Theravance Inc | Quinolinone compounds as 5-HT4 receptor agonists |
| CA2601458C (fr) * | 2005-03-15 | 2011-04-26 | Pfizer Inc. | Derives de benzimidazolone en tant que ligands de recepteur cb2 |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7317022B2 (en) * | 2005-06-07 | 2008-01-08 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists |
| US8283364B2 (en) * | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
| WO2007036711A1 (fr) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Benzimidazolones exerçant une activite au niveau du recepteur m1 |
| WO2007036718A2 (fr) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine |
| AU2006308889A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| TW200736227A (en) * | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
| EP1984027B1 (fr) * | 2006-01-24 | 2015-12-30 | R-Tech Ueno, Ltd. | Composition pharmaceutique comprenant un composé bicyclique et procédé pour stabiliser ce composé bicyclique |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| US20080318964A1 (en) * | 2007-06-19 | 2008-12-25 | Protia, Llc | Deuterium-enriched eszopiclone |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社ＡｓｋＡｔ | 認知症治療のための５−ｈｔ４受容体アゴニスト |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US20120143119A1 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of Serotonin Receptor Antagonists By Microinjection Systems |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CA2867043A1 (fr) | 2012-05-03 | 2013-11-07 | Novartis Ag | Sel de l-malate de derives de 2,7-diaza-spiro[4.5]dec-7-yle et ses formes cristallines a titre d'agonistes des recepteurs de ghreline |
| WO2017093890A1 (fr) * | 2015-11-30 | 2017-06-08 | Piramal Enterprises Limited | Formulation de comprimé à base de clobazam et son procédé de préparation |
| WO2022086238A1 (fr) * | 2020-10-23 | 2022-04-28 | Hk Inno.N Corporation | Comprimé à désintégration orale comprenant un composé dérivé de benzimidazole et procédé de préparation associé |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US63716A (en) * | 1867-04-09 | Improved cheery stoner | ||
| CH566987A5 (fr) * | 1972-04-21 | 1975-09-30 | Ciba Geigy Ag | |
| US3945953A (en) * | 1972-04-21 | 1976-03-23 | Ciba-Geigy Corporation | ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use |
| DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
| US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0522914A1 (fr) * | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| EP0667867A1 (fr) * | 1992-11-05 | 1995-08-23 | Smithkline Beecham Plc | Derives de piperidine utiles comme antagonistes de recepteur de 5-ht4 |
| TW252206B (fr) * | 1993-09-01 | 1995-07-21 | Philips Electronics Nv | |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU9309898A (en) | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
| US6069152A (en) | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6420410B1 (en) * | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| JPWO2002053568A1 (ja) * | 2000-12-28 | 2004-05-13 | 持田製薬株式会社 | スピロ結合を有する三環系化合物を有効成分とするコレステロール生合成阻害剤 |
| SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| UA86204C2 (uk) * | 2003-09-03 | 2009-04-10 | Пфайзер Инк. | Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| CA2569654C (fr) * | 2004-06-15 | 2010-12-21 | Pfizer Inc. | Derives de benzimidazolone d'acide carboxylique |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2004
- 2004-08-20 UA UAA200602293A patent/UA86204C2/uk unknown
- 2004-08-20 KR KR1020067004335A patent/KR100738784B1/ko not_active Expired - Lifetime
- 2004-08-20 WO PCT/IB2004/002741 patent/WO2005021539A1/fr not_active Ceased
- 2004-08-20 MX MXPA06002550A patent/MXPA06002550A/es active IP Right Grant
- 2004-08-20 SI SI200431820T patent/SI1664036T1/sl unknown
- 2004-08-20 BR BRPI0414105A patent/BRPI0414105B8/pt not_active IP Right Cessation
- 2004-08-20 PL PL04744319T patent/PL1664036T3/pl unknown
- 2004-08-20 EP EP04744319A patent/EP1664036B1/fr not_active Expired - Lifetime
- 2004-08-20 PT PT04744319T patent/PT1664036E/pt unknown
- 2004-08-20 HR HR20120077T patent/HRP20120077T1/hr unknown
- 2004-08-20 CN CNB2004800252755A patent/CN100482659C/zh not_active Expired - Fee Related
- 2004-08-20 CA CA2537127A patent/CA2537127C/fr not_active Expired - Lifetime
- 2004-08-20 RS YUP-2006/0145A patent/RS20060145A/sr unknown
- 2004-08-20 AT AT04744319T patent/ATE539077T1/de active
- 2004-08-20 AP AP2006003536A patent/AP2184A/xx active
- 2004-08-20 OA OA1200600069A patent/OA13248A/en unknown
- 2004-08-20 ES ES04744319T patent/ES2377484T3/es not_active Expired - Lifetime
- 2004-08-20 DK DK04744319.7T patent/DK1664036T3/da active
- 2004-08-20 AU AU2004268840A patent/AU2004268840B9/en not_active Ceased
- 2004-08-20 GE GEAP20049270A patent/GEP20084527B/en unknown
- 2004-08-20 JP JP2006525197A patent/JP3983269B1/ja not_active Expired - Fee Related
- 2004-08-20 EA EA200600327A patent/EA009457B1/ru not_active IP Right Cessation
- 2004-08-31 PE PE2004000831A patent/PE20050874A1/es not_active Application Discontinuation
- 2004-09-01 AR ARP040103133A patent/AR045552A1/es not_active Application Discontinuation
- 2004-09-02 PA PA20048610601A patent/PA8610601A1/es unknown
- 2004-09-02 UY UY28496A patent/UY28496A1/es not_active Application Discontinuation
- 2004-09-02 GT GT200400174A patent/GT200400174A/es unknown
- 2004-09-02 TW TW093126507A patent/TW200510332A/zh unknown
- 2004-09-02 US US10/933,629 patent/US7776885B2/en active Active
- 2004-09-03 NL NL1026959A patent/NL1026959C2/nl not_active IP Right Cessation
-
2006
- 2006-02-09 IS IS8289A patent/IS8289A/is unknown
- 2006-02-13 IL IL173705A patent/IL173705A/en not_active IP Right Cessation
- 2006-02-14 ZA ZA200601324A patent/ZA200601324B/en unknown
- 2006-03-02 CR CR8267A patent/CR8267A/es not_active Application Discontinuation
- 2006-03-03 MA MA28851A patent/MA28021A1/fr unknown
- 2006-03-03 EC EC2006006407A patent/ECSP066407A/es unknown
- 2006-03-03 TN TNP2006000073A patent/TNSN06073A1/en unknown
- 2006-04-03 NO NO20061519A patent/NO20061519L/no not_active Application Discontinuation
-
2010
- 2010-05-06 IL IL205600A patent/IL205600A0/en unknown
- 2010-05-06 IL IL205599A patent/IL205599A0/en unknown
- 2010-07-07 US US12/831,713 patent/US20100273794A1/en not_active Abandoned
-
2012
- 2012-02-06 CY CY20121100124T patent/CY1112321T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28021A1 (fr) | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 | |
| MA29260B1 (fr) | Derives d'oxindole servant d'agonistes du recepteur 5ht4 | |
| US20050009812A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
| EA200400589A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| NO20073766L (no) | Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav | |
| US20070225277A1 (en) | Treatment of pain | |
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| MA28667B1 (fr) | Derives d'acide benzimidazolonecarboxylique | |
| JP2009539799A (ja) | Ｃｇｒｐ拮抗薬 | |
| US20060258713A1 (en) | Treatment of pain | |
| US9115123B2 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| DE602006010563D1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| KR20080105092A (ko) | 피롤 유도체 또는 그의 염 | |
| FR2792199A1 (fr) | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur | |
| GB2397301A (en) | Substituted 1,3,5-triazine derivatives | |
| NO943101L (no) | 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist | |
| CA2659754A1 (fr) | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 | |
| DOP2004000986A (es) | Compuestos de bencimidazolona que tienen actividad del receptor 5ht-4 | |
| US20050080076A1 (en) | N-desmethyl levomepromazine | |
| EP0621781A1 (fr) | Utilisation de derives de 3-arylindole et de 3-arylindazole dans le traitement de psychoses | |
| JPH10175972A (ja) | キナゾリン系化合物 | |
| ZA200503822B (en) | 3-(cyclopenten-1-yl)-benzyl or 3-(cyclopenten-1-yl)-hetero-arylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | |
| WO1992011011A1 (fr) | Utilisation de certains derives de glutarimide dans le traitement de la depression et des etats maniaques | |
| TH76314A (th) | สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด | |
| TH106943A (th) | สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์ |